XENE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XENE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-01), Xenon Pharmaceuticals's current share price is $38.09. Xenon Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.26. Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 11.68.
The historical rank and industry rank for Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Xenon Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 36.85. The lowest was 11.96. And the median was 20.06.
XENE's Cyclically Adjusted PB Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Xenon Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $11.764. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.26 for the trailing ten years ended in Mar. 2024.
The historical data trend for Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 17.99 | 17.28 | 14.00 | 15.27 | 13.19 |
For the Biotechnology subindustry, Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 38.09 | / | 3.26 | |
= | 11.68 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenon Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Xenon Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:
Adj_Book | = | Book Value per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 11.764 | / | 126.2576 | * | 126.2576 | |
= | 11.764 |
Current CPI (Mar. 2024) = 126.2576.
Xenon Pharmaceuticals Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201406 | 1.996 | 99.473 | 2.533 |
201409 | -4.971 | 99.394 | -6.315 |
201412 | 5.132 | 98.367 | 6.587 |
201503 | -5.522 | 99.789 | -6.987 |
201506 | -5.851 | 100.500 | -7.351 |
201509 | -5.849 | 100.421 | -7.354 |
201512 | 4.243 | 99.947 | 5.360 |
201603 | -6.289 | 101.054 | -7.858 |
201606 | -6.674 | 102.002 | -8.261 |
201609 | -5.789 | 101.765 | -7.182 |
201612 | 3.564 | 101.449 | 4.436 |
201703 | -6.481 | 102.634 | -7.973 |
201706 | -6.856 | 103.029 | -8.402 |
201709 | -7.253 | 103.345 | -8.861 |
201712 | 1.997 | 103.345 | 2.440 |
201803 | 0.471 | 105.004 | 0.566 |
201806 | 1.632 | 105.557 | 1.952 |
201809 | 3.939 | 105.636 | 4.708 |
201812 | 3.711 | 105.399 | 4.445 |
201903 | 3.282 | 106.979 | 3.873 |
201906 | 2.912 | 107.690 | 3.414 |
201909 | 2.584 | 107.611 | 3.032 |
201912 | 2.994 | 107.769 | 3.508 |
202003 | 5.156 | 107.927 | 6.032 |
202006 | 5.188 | 108.401 | 6.043 |
202009 | 4.980 | 108.164 | 5.813 |
202012 | 4.673 | 108.559 | 5.435 |
202103 | 6.556 | 110.298 | 7.505 |
202106 | 6.062 | 111.720 | 6.851 |
202109 | 5.824 | 112.905 | 6.513 |
202112 | 10.503 | 113.774 | 11.655 |
202203 | 10.212 | 117.646 | 10.960 |
202206 | 12.625 | 120.806 | 13.195 |
202209 | 12.042 | 120.648 | 12.602 |
202212 | 11.528 | 120.964 | 12.032 |
202303 | 10.885 | 122.702 | 11.200 |
202306 | 10.146 | 124.203 | 10.314 |
202309 | 9.793 | 125.230 | 9.873 |
202312 | 12.311 | 125.072 | 12.428 |
202403 | 11.764 | 126.258 | 11.764 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Gary Patou | director | |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Gillian Cannon | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Justin D. Gover | director | SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ |
Patrick Machado | director | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Elizabeth A. Garofalo | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Steven Gannon | director | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8 |
Simon N. Pimstone | director | 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8 |
Ian Mortimer | director, officer: PRESIDENT & CEO | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8 |
Christopher John Kenney | officer: Chief Medical Officer | 200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W |
Andrea Difabio | officer: Chief Legal Officer | BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451 |
Sherry Aulin | officer: Chief Financial Officer | 200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W |
Sherrington Robin | officer: SVP Bus. & Corp. Development | C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8 |
James R. Empfield | officer: SVP, Drug Discovery | 200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W |
Seggern Christopher Von | officer: Chief Commercial Officer | 200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W |
From GuruFocus
By Value_Insider Value_Insider • 12-02-2022
By sperokesalga sperokesalga • 05-09-2023
By Marketwired • 10-06-2023
By Marketwired • 09-14-2023
By GuruFocus Research • 05-28-2023
By sperokesalga sperokesalga • 04-21-2023
By Stock market mentor Stock market mentor • 01-04-2023
By sperokesalga sperokesalga • 02-08-2023